The study reviewed US medical claims databases from 2005 to 2021 and compared CVD outcomes in narcolepsy patients and ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

Some common narcolepsy comorbidities include obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD), restless legs syndrome (RLS), anxiety, and depression. Comorbidities ...

USA: A retrospective cohort study using Medicare and commercial insurance data has found that narcolepsy is associated with increased risks of high blood pressure, hyperlipidemia, diabetes, and ...

Narcolepsy is a condition causing patients to experience excessive sleepiness during the day and sleep disruption overnight. Dream sleep (Rapid Eye Movement sleep or REM sleep) phenomena occur at odd ...

From baseline, patients treated with AXS-12 had an 83% reduction in cataplexy attacks at the end of 5 weeks compared with a 66% reduction with placebo (rate ratio [RR] 0.49, P=0.0 ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. | The company ...

Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate ...

YouTube has transitioned from a place with amateur videos to one that's become a major force in TV with billions of global ...

Xyrem, a medication approved in the U.S., is used for the treatment of excessive daytime sleepiness and sudden loss of muscle control in patients suffering from narcolepsy, a chronic neurological ...